These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25975224)

  • 1. The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer.
    Butkiewicz D; Krześniak M; Drosik A; Giglok M; Gdowicz-Kłosok A; Kosarewicz A; Rusin M; Masłyk B; Gawkowska-Suwińska M; Suwiński R
    Int J Cancer; 2015 Nov; 137(10):2332-42. PubMed ID: 25975224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
    Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
    [No Abstract]   [Full Text] [Related]  

  • 3. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
    Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
    Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
    [No Abstract]   [Full Text] [Related]  

  • 4. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
    Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
    Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of
    Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
    Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
    [No Abstract]   [Full Text] [Related]  

  • 6. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer.
    Yang J; Xu T; Gomez DR; Yuan X; Nguyen QN; Jeter M; Song Y; Komaki R; Hu Y; Hahn SM; Liao Z
    Cancer Med; 2018 Jun; 7(6):2247-2255. PubMed ID: 29745043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
    Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
    Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
    Liu JY; Zhu BR; Wang YD; Sun X
    Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
    Geng N; Ding CM; Liu ZK; Song S; Hu WX
    Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy.
    Wen J; Liu H; Wang L; Wang X; Gu N; Liu Z; Xu T; Gomez DR; Komaki R; Liao Z; Wei Q
    J Thorac Oncol; 2018 May; 13(5):660-675. PubMed ID: 29454863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.
    Uzunoglu FG; Kaufmann C; Wikman H; Güngör C; Bohn BA; Nentwich MF; Reeh M; Pantel K; Bockhorn M; Kutup A; Mann O; Izbicki JR; Vashist YK
    Ann Surg Oncol; 2012 Jul; 19(7):2159-68. PubMed ID: 22395975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Liu L; Zhou F; Ren S; Chen X; Li X; Li W; Zhou C
    Asia Pac J Clin Oncol; 2016 Jun; 12(2):e339-46. PubMed ID: 25131817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis.
    Scherf DB; Dally H; Müller P; Werle-Schneider G; Jäger B; Edler L; Tuengerthal S; Fischer JR; Drings P; Bartsch H; Risch A
    Eur Respir J; 2010 Feb; 35(2):381-90. PubMed ID: 19643940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
    Kim MK; Suh C; Chi HS; Cho HS; Bae YK; Lee KH; Lee GW; Kim IS; Eom HS; Kong SY; Bae SH; Ryoo HM; Shin IH; Mun YC; Chung H; Hyun MS
    Cancer Sci; 2012 Mar; 103(3):497-503. PubMed ID: 22129133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship of metalloproteinase gene polymorphisms and lung cancer.
    Sanli M; Akar E; Pehlivan S; Bakır K; Tuncozgur B; Isik AF; Pehlivan M; Elbeyli L
    J Surg Res; 2013 Aug; 183(2):517-23. PubMed ID: 23465389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NRP-1 and KDR polymorphisms are associated with survival time in patients with advanced gastric cancer.
    Zhuo YJ; Shi Y; Wu T
    Oncol Lett; 2019 Nov; 18(5):4629-4638. PubMed ID: 31611971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients.
    Sullivan I; Riera P; Andrés M; Altés A; Majem M; Blanco R; Capdevila L; Barba A; Barnadas A; Salazar J
    Angiogenesis; 2019 Aug; 22(3):433-440. PubMed ID: 30977010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
    Zhao X; Wang X; Wu W; Gao Z; Wu J; Garfield DH; Wang H; Wang J; Qian J; Li H; Jin L; Li Q; Han B; Lu D; Bai C
    Cancer; 2012 Jul; 118(14):3587-98. PubMed ID: 22072145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.